Clinical Presentations of Multiple Sclerosis at Royal Commission Hospital Yanbu Kingdom of Saudi Arabia

Authors

  • Dr. Sajjad Naseer Akhtar Saeed Medical and Dental, College, Bahria Town, Lahore
  • Dr. Farooq Saeed Khan Akhtar Saeed Medical and Dental, College, Bahria Town, Lahore
  • Dr. Javed Shabkhez Rab Akhtar Saeed Medical and Dental, College, Bahria Town, Lahore
  • Dr. Javed Iqbal Zuberi Akhtar Saeed Medical and Dental, College, Bahria Town, Lahore
  • Dr. Sumayya Sajjad Akhtar Saeed Medical and Dental, College, Bahria Town, Lahore
  • Dr. Muhammad Anwer Akhtar Saeed Medical and Dental, College, Bahria Town, Lahore
  • Dr. Zafar Iqbal Akhtar Saeed Medical and Dental, College, Bahria Town, Lahore
  • Dr. Shazina Siddiqui Akhtar Saeed Medical and Dental, College, Bahria Town, Lahore

Keywords:

Multiple Sclerosis, demyelinating disease

Abstract

Introduction: Multiple sclerosis (MS) is an important cause of long standing disability especially in adult females. The incidence is more in Europe. In Europe specially in USA and UK the prevalence is about 120/ 100,000. The annual incidence is around 7 per 100,000, while the life time risk of developing MS is about 1in 400. The incidence of MS is higher in northern Europeans, and the disease is about twice as common in females. Objectives: To study various ways the patients of multiple sclerosis presented in the department of neurology at
Objectives: To study various ways the patients of multiple sclerosis presented in the department of neurology at Royal commission hospital Yanbu, Kingdom of Saudi Arabia.
Materials and Methods: This is new as well newly diagnosed patients who presented in the emergency as well as outpatient department of neurology at Royal Commission hospital Yanbu, Kingdom of Saudi Arabia. Yanbu is one of the biggest industrial city of Saudi Arabia. Duration of study was two years; from January 2011 to December 2012. The study included 50 patients. We diagnosed 45 patients ourselves and 5 patients were following in the neurology OPD.
Results: The age range was 17 – 58; 38 patients were females and 2 were males. Most of the affected patients were in the age range of 17 – 36. Mean duration of illness was from 1 – 9 years. In most of the patients, the initial presentation was weakness and visual loss. Most of the patients were started on interferons and they has very good outcome.
Conclusions: Multiple sclerosis involves both brain and spinal cord. Early diagnosis and treatment promises good outcome and rehabilitation. The new treatment modalities have played revolutionary role in modulating the disease.

Abbreviations: MS = Multiple sclerosis.

Author Biographies

Dr. Sajjad Naseer, Akhtar Saeed Medical and Dental, College, Bahria Town, Lahore

Department of Internal Medicine

Dr. Farooq Saeed Khan, Akhtar Saeed Medical and Dental, College, Bahria Town, Lahore

Department of Internal Medicine

Dr. Javed Shabkhez Rab, Akhtar Saeed Medical and Dental, College, Bahria Town, Lahore

Department of Internal Medicine

Dr. Javed Iqbal Zuberi, Akhtar Saeed Medical and Dental, College, Bahria Town, Lahore

Department of Internal Medicine

Dr. Sumayya Sajjad, Akhtar Saeed Medical and Dental, College, Bahria Town, Lahore

Department of Internal Medicine

Dr. Muhammad Anwer, Akhtar Saeed Medical and Dental, College, Bahria Town, Lahore

Department of Internal Medicine

Dr. Zafar Iqbal, Akhtar Saeed Medical and Dental, College, Bahria Town, Lahore

Department of Internal Medicine

Dr. Shazina Siddiqui, Akhtar Saeed Medical and Dental, College, Bahria Town, Lahore

Department of Internal Medicine

References

1. Compston A, Coles A. “Multiple sclerosis”. Lancet (October 2008); 372 (9648): 1502–17.
2. Compston A, Coles A. “Multiple sclerosis” Lancet (April 2002); 359 (9313): 1221–31.
3. Murray ED, Buttner EA, Price BH. “Depression and Psychosis in Neurological Practice”. In Daroff R, Fenichel G, Jankovic J, Mazziotta J. Bradley’s neurology in clinical practice. (6th ed). Philadelphia, PA: Elsevier/ Saunders 2012.
4. Lublin FD, Reingold SC. “Defining the clinical course of multiple sclerosis: results of an international survey” Neurology (April 1996); 46 (4): 907–11.
5. Nakahara J, Maeda M, Aiso S, Suzuki N. “Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy.” Clinical reviews in allergy and immunology (February 2012); 42 (1): 26–34.
6. Ascherio A, Munger KL. “Environmental risk factors for multiple sclerosis. Part I: the role of infection”. Annals of Neurology (April 2007); 61 (4): 288–99.
7. Weinshenker BG. “Natural history of multiple sclerosis”. Annals of Neurology 1994; 36 (Suppl): S6–11.
8. Berer K, Krishnamoorthy G. “Microbial view of central nervous system autoimmunity”. FEBS Letters, April 2014; S0014-5793 (14): 00293–2.
9. World Health Organization. Atlas: Multiple Sclerosis Resources in the World 2008 (PDF). Geneva: World Health Organization, 2008; pp. 15–16.
10. GBD 2013 Mortality and Causes of Death, Collaborators. “Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.” Lancet, 17 December 2014; 385: 117–171 (table 2).
11. Milo R, Kahana E. “Multiple sclerosis: geoepidemiology, genetics and the environment”. Autoimmun Rev March 2010; 9 (5): A387–94.
12. Clanet M. “Jean – Martin Charcot. 1825 to 1893” (PDF). Int MS J June 2008; 15 (2): 59–61.
13. *Charcot, J. “Histologie de la sclerose en plaques”. Gazette des hopitaux, Paris, 1868; 41: 554–5.
14. Kurtzke JF. “Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)”. Neurology, 1983; 33 (11): 1444–52.
15. Amato MP, Ponziani G. “Quantification of impairment in MS: discussion of the scales in use”. Mult. Scler. August 1999; 5 (4): 216–9.
16. Rudick RA, Cutter G, Reingold S. “The multiple sclerasis functional composite: a new clinical outcome measure for multiple sclerosis trials”. Mult. Scler. October 2002; 8 (5): 359–65.
17. Tsang BK, Macdonell R. “Multiple sclerosis- diagnosis, management and prognosis”. Australian family physiccian, December 2011; 40 (12): 948–55.
18. Tataru N, Vidal C, Decavel P, Berger E, Rumbach L. “Limited impact of the summer heat wave in France (2003) on hospital admissions and relapses for multiple sclerosis”. Neuroepidemiology, 2006; 27 (1): 28–32.
19. Heesen C, Mohr DC, Huitinga I, Bergh FT, Gaab J, Otte C, Gold SM. “Stress regulation in multiple sclerosis: current issues and concepts”. Mult. Scler. March 2007; 13 (2): 143–8.
20. Martinelli V. “Trauma, stress and multiple sclerosis”. Neurol. Sci. 2000; 21 (4 Suppl. 2): S849–52.
21. Marrie RA. “Environmental risk factors in multiple sclerosis aetiology”. Lancet Neurol. December 2004; 3 (12): 709–18.
22. Pugliatti M, Sotgiu S, Rosati G. “The worldwide prevalence of multiple sclerosis”. Clin Neurol Neurosurg. July 2002; 104 (3): 182–91.
23. Grimaldi LM, Salemi G, Grimaldi G, et al. “High incidence and increasing prevalence of MS in Enna (Sicily), southern Italy.” Neurology, 27 November 2001; 57 (10): 1891–3.
24. Ascherio A, Munger KL. “Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors”. Annals of Neurology, June 2007; 61 (6): 504–13.
25. Ascherio A, Munger KL, Simon KC. “Vitamin D and multiple sclerosis”. Lancet Neurol. June 2010; 9 (6): 599–612.
26. Ascherio A, Munger KL, Simon KC. “Vitamin D and multiple sclerosis”. Lancet Neurol. June 2010; 9 (6): 599–612.

Downloads

Published

2015-12-25

Issue

Section

Original Articles